Rashmi Singh

Employment

• Banaras Hindu University Professor
  2007 - Present

Education

Education history is unavailable.

Projects & Funding

Projects & funding information is unavailable.

Publications (26)

• Intranasal curcumin and sodium butyrate modulates airway inflammation and fibrosis via HDAC inhibition in allergic asthma
  Cytokine 2022 DOI: 10.1016/j.cyto.2021.155720
  +Save
• Intranasal micellar curcumin for the treatment of chronic asthma
  Journal of Drug Delivery Science and Technology 2022 DOI: 10.1016/j.jddst.2021.102922
  +Save
• Protective effects of intranasal curcumin on silica-induced lung damage
  Cytokine 2022 DOI: 10.1016/j.cyto.2022.155949
  +Save
• Intranasal curcumin and dexamethasone combination ameliorates inflammasome (NLRP3) activation in lipopolysachharide exposed asthma exacerbations
  Toxicology and Applied Pharmacology 2022 DOI: 10.1016/j.taap.2021.115861
  +Save
• Curcumin Modulates Paraquat-Induced Epithelial to Mesenchymal Transition by Regulating Transforming Growth Factor-β (TGF-β) in A549 Cells
  Inflammation 2019 DOI: 10.1007/s10753-019-01006-0
  +Save
• Intranasal curcumin protects against LPS-induced airway remodeling by modulating toll-like receptor-4 (TLR-4) and matrixmetalloproteinase-9 (MMP-9) expression via affecting MAP kinases in mouse model
  Inflammopharmacology 2019 DOI: 10.1007/s10787-018-0544-3
  +Save
• Paraquat-induced oxidative stress and lung inflammation
  Oxidative Stress in Lung Diseases 2019 DOI: 10.1007/978-981-32-9366-3_11
  +Save
• Combination Therapy with Curcumin Alone Plus Piperine Ameliorates Ovalbumin-Induced Chronic Asthma in Mice
  Inflammation 2018 DOI: 10.1007/s10753-018-0836-1
  +Save
• Intranasal curcumin regulates chronic asthma in mice by modulating NF-ĸB activation and MAPK signaling
  Phytomedicine 2018 DOI: 10.1016/j.phymed.2018.06.022
  +Save
• Curcumin inhibits lipopolysaccharide (LPS)-induced endotoxemia and airway inflammation through modulation of sequential release of inflammatory mediators (TNF-α and TGF-β1) in murine model
  Inflammopharmacology 2017 DOI: 10.1007/s10787-017-0334-3
  +Save